Skip to main content

Medication Overuse Headache

A Focus on Analgesics, Ergot Alkaloids and Triptans

Drug Safety volume 24, pages 921–927 (2001)Cite this article

Abstract

Medication overuse headache (MOH, formerly known as drug-induced headache) is a well known disorder following the frequent use of analgesics or any other antiheadache drug including serotonin 5-HT1B/D agonists (triptans).

Recent studies suggest clinical features of MOH depend on the substance class that has been overused. The delay between the frequent intake of any antiheadache drug and daily headache is shortest for triptans (mean 1.7 years), longer for ergot alkaloids (mean 2.7 years) and longest for analgesics (mean 4.9 years).

Treatment includes withdrawal followed by structured acute therapy and initiation of specific prophylactic treatment for the underlying primary headache. The relapse rate within 6 months after successful withdrawal is about 30% and increases steadily up to 50% after 5 years.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I

References

  1. Peters GA, Horton BT. Headache: with special reference to exessive use of ergotamine preparations and withdrawl effects. Mayo Clin Proc 1951; 26: 214–26

    Google Scholar 

  2. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1–96

    Google Scholar 

  3. Diener HC, Wilkinson M, editors. Drug-induced headache. New York: Springer Verlag, 1988

    Google Scholar 

  4. Kaube H, May A, Pfaffenrath V, et al. Sumatriptan misuse in daily chronic headache. BMJ 1994; 308: 1573–4

    PubMed  Article  CAS  Google Scholar 

  5. Limmroth V, Kazarawa S, Fritsche G, et al. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999; 353: 378

    PubMed  Article  CAS  Google Scholar 

  6. Castillo J, Munoz P, Guitera V, et al. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190–6

    PubMed  Article  CAS  Google Scholar 

  7. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000; 54: 314–9

    PubMed  Article  CAS  Google Scholar 

  8. Robinson RG. Pain relief for headaches. Is self-medication a problem? Can Fam Physician 1993 Apr; 39: 867–8

    PubMed  CAS  Google Scholar 

  9. Granella F, Farina S, Malferrari G, et al. Drug abuse in chronic headache: a clinico-epidemiologic study. Cephalalgia 1987; 7: 15–9

    PubMed  Article  CAS  Google Scholar 

  10. Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener HC, {Wilkinson M}, editors. MOH. Berlin: Springer, 1988: 20–8

    Google Scholar 

  11. Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36: 14–9

    PubMed  Article  CAS  Google Scholar 

  12. Gutzwiller F, Zemp E. Der Analgetikakonsum in der Bevölkerung und socioökonomische Aspekte des Analgetikaabusus. In: Mihatsch MJ, editor. Stutgart; Das Analgetikasyndrom Thieme, 1986: 197

  13. Schwarz A, Farber U, Glaeske G. Daten zu Analgetikakonsum und Analgetikanephropathie in der Bundesrepublik. Offentl Gesundheitswes 1985; 47: 298

    PubMed  CAS  Google Scholar 

  14. Gaist D. Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 1999; 19: 735–61

    PubMed  Article  CAS  Google Scholar 

  15. Evers S, Bauer B, Suhr B, et al. The epidemiology of sumatriptan abuse. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment: trial methodology and new drugs. Philadelphia: Lippincott-Raven, 1997: 149–52

    Google Scholar 

  16. Diener HC, Dahlöf CGH. Headache associated with chronic use of substances. Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 1999: 871–8

    Google Scholar 

  17. Catarci T, Fiacco F, Argentino C, et al. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 1994; 14: 374–5

    PubMed  Article  CAS  Google Scholar 

  18. Gaist D, Hallas J, Sindrup SH, et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996; 3: 161–5

    Article  Google Scholar 

  19. Gaist D, Tsiropoulus I, Sindrup SH, et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ 1998; 316: 1352–3

    PubMed  Article  CAS  Google Scholar 

  20. Pini LA, Trenti T. Case report: does chronic use of sumatriptan induce dependence? Headache 1994; 34: 600–1

    PubMed  Article  CAS  Google Scholar 

  21. Katsarava Z, Fritsche G, Diener HC, et al. MOH (DIH) following the use of different triptans. Cephalalgia 2000; 20: 293

    Google Scholar 

  22. Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular analgesic use? Cephalalgia 2000; 20: 294

    Google Scholar 

  23. Lance F, Parkes C, Wilkinso M. Does analgesic abuse cause headache de novo? Headache 1988; 38: 61–2

    Article  Google Scholar 

  24. Diamond S. Caffeine as an analgesic adjuvant in the treatment of headache. Headache 1999; 44: 4778–9

    Google Scholar 

  25. Migliardi JR, Armellino JJ, Friedmann M, et al. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56: 576–86

    PubMed  Article  CAS  Google Scholar 

  26. Silverman K, Evans SM, Strain EC, et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327: 1109–14

    PubMed  Article  CAS  Google Scholar 

  27. van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. BMJ 1990; 300: 1558–9

    PubMed  Article  Google Scholar 

  28. Feinstein AR, Heinemann LA, Dalessio D, et al. Do caffein-econtaining analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000; 68: 457–67

    PubMed  Article  CAS  Google Scholar 

  29. Fisher MA, Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 1997; 48: 1156–60

    PubMed  Article  CAS  Google Scholar 

  30. Ziegler DK. Opiate und opioid use in patients with refractory headache. Cephalalgia 1994; 14: 5–10

    PubMed  Article  CAS  Google Scholar 

  31. John GW, Pauwels PJ, Perez M, et al. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther 1999; 290: 83–95

    PubMed  CAS  Google Scholar 

  32. Dichgans J, Diener HC, Gerber WD, et al. Analgetika-induzierter Dauerkopfschmerz. Dtsch Med Wochenschr 1984; 109: 369–73

    PubMed  Article  CAS  Google Scholar 

  33. Gobel H, Stolze H, Heinze A, et al. Easy therapeutical management of sumatriptan-induced daily headache. Neurology 1996; 47: 297–8

    PubMed  Article  CAS  Google Scholar 

  34. Katsarava Z, Fritsche G, Mueßig M, et al. Clinical features of withdrawal headache following overuse of triptans in comparison to other anti-headache drugs. Neurology. In press

  35. Haag G, Baar H, Grotemeyer KH, et al. Prophylaxe und Therapie des medikamenteninduzierten Dauerkopfschmerzes. Schmerz 1999; 13: 52–7

    PubMed  Article  CAS  Google Scholar 

  36. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open labelled study. Headache 1991; 31: 71–4

    PubMed  Article  CAS  Google Scholar 

  37. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000; 20: 107–13

    PubMed  Article  CAS  Google Scholar 

  38. Diener HC, Haab J, Peters C, et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from MOH. Headache 1990; 31: 205–9

    Article  Google Scholar 

  39. Mathew NT. Amelioration of ergotamine withdrawal with naproxen. Headache 1987; 27: 130–3

    PubMed  Article  CAS  Google Scholar 

  40. Mathew NT, Kurman R, Perez F. Drug induced refractory headache-clinical features and management. Headache 1990; 30: 634–8

    PubMed  Article  CAS  Google Scholar 

  41. Linton-Dahlof P, Linde M, Dahlof C. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study. Cephalalgia 2000; 20: 658–62

    PubMed  CAS  Google Scholar 

  42. Baumgartner C, Wessely P, Bingöl C, et al. Longterm prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989; 29: 510–4

    PubMed  Article  CAS  Google Scholar 

  43. Diener HC, Dichgans J, Scholz E, et al. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9–14

    PubMed  Article  CAS  Google Scholar 

  44. Schnider P, Aull S, Baumgartner C, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia 1996; 16: 481–5

    PubMed  Article  CAS  Google Scholar 

  45. Fritsche G, Eberl A, Katsarava Z, et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229–35

    PubMed  Article  CAS  Google Scholar 

  46. Tfelt-Hansen P, Krabbe AA. Ergotamine abuse: do patients benefit from withdrawal? Cephalalgia 1981; 1: 29–31

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, University Hospital Essen, University of Essen, Hufelandstr. 55, 45122, Essen, Germany

    Zaza Katsarava, Hans-Christoph Diener &  Volker Limmroth

Authors
  1. Zaza Katsarava
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Christoph Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Limmroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Volker Limmroth.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Katsarava, Z., Diener, HC. & Limmroth, V. Medication Overuse Headache. Drug-Safety 24, 921–927 (2001). https://doi.org/10.2165/00002018-200124120-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124120-00005

Keywords

  • Migraine
  • Sumatriptan
  • Zolmitriptan
  • Chronic Daily Headache
  • International Headache Society